PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) …

Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong
antioxidant and anticancer properties that is present in high quantity in a variety of berries …

The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …

Purpose Consolidation durvalumab after chemoradiation therapy (CRT) has improved
patient outcomes in stage III non-small cell lung cancer (NSCLC) since the practice …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line
therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive …

Objectives The burden of epidermal growth factor receptor (EGFR) exon 20 insertion
mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic …

Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

Introduction Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI).
Durvalumab is an anti–programmed death ligand 1 monoclonal antibody. The phase III …

Urinary tests have been used as noninvasive, cost-effective tools for screening, diagnosis
and monitoring of diseases since ancient times. As we progress through the 21st century …